By Suvarna Bhatt
San Francisco, (BioSpace) – Shire US Inc. announces the discontinuation of Ethmozine (moricizine hydrochloride) 200mg, 250g, and 300mg tablets due to decreased market demand effective August 28, 2007.
In a letter to healthcare professionals, Shire states the discontinuation is not due to any safety or efficacy concerns.
To view the letter issued to healthcare professionals, please visit: http://www.fda.gov/cder/drug/shortages/ShireDiscontiuationLetter.pdf
